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There is increasing pressure to incorporate health economics and
quality oflife assessment into clinical trials ofinterventions for the
treatment of cancer. This pressure has arisen from the interests of
agencies funding research (such as the MRC, the NHS R&D
programme and the pharmaceutical industry) and the consumers of
research information. These include local and national clinical
decision makers, regulatory and reimbursement agencies and
patients. However, the integration of quality of life and health
economic assessments into the clinical trial process is not straight-
forward and has raised several issues of concern to all involved in
health service and clinical research. Broadly speaking, there are
three main sources of concern. First, there are uncertainties as to
when to include such evaluations in clinical trials. Secondly, there
are concerns about methodology to ensure the validity of health
economics and quality of life aspects of clinical trial design.
Thirdly, the increasing size required for clinical trials has led to
concerns about the feasibility oftrials and the willingness ofclini-
cians and patients to participate if substantial additional data are
collected. A major issue is to ensure that the inclusion of health
economics and quality of life assessment does not prejudice long-
term patient health by inefficient evaluation of new and existing
interventions.
The issues of quality of life and health economics are often
considered together in the context of clinical trials and, indeed,
some types of economic appraisal may use particular kinds of
quality of life measures to assess benefits in relation to costs.
However, overall it is important to recognize that, to a consider-
able extent, quality of life and economic data address distinct
questions. For the most part, they are therefore examined sepa-
rately in this paper.
This paper has emerged from what may be considered an
informal 'nominal group' technique, whereby the extent of
consensus on a complex question is assessed (Fitzpatrick and
Boulton, 1994). The UKCCCR held a 1-day workshop to bring
together clinicians, health economists, experts in quality of life
evaluation, statisticians and health care purchasers to discuss the
role of health economics and quality of life in cancer trials and to
make recommendations to the Trials Committee and the Main
Committee of the UKCCCR. The authors of this paper were
invited to summarize the discussions that occurred at the meeting.
This took the form of an earlier draft of the current paper, which
was then circulated to individuals who had attended. Participants
were invited to send in written comments, which were used to
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revise the paper. A revised version was also circulated and again
modified in response to additional comments. Because there was
no basic agreement on two major issues, it seemed more accurate
and informative to report these two points at the end of this paper
as issues requiring further research and, possibly, more focused
attention in further discussions. These two unresolved issues are
(1) defining occasions when quality of life and economic data are
not needed in trials and (2) defining the scale and extent of data
collection required to address quality of life and economic
questions in trials.
WHEN TO INCLUDE QUALITY OF LIFE
It is increasingly recognized that interventions for cancer are
concerned with the quality of life of patients as well as survival.
Clinical trials will also therefore increasingly address such end
points. However, as with any other element in a clinical trial, it is
essential that quality of life measures are included because they
address an important question in a relevant way, rather than as a
ritualistic feature to placate funding bodies or other parties. There
are useful discussions of the kinds of trials in which quality of life
is particularly relevant (Gotay et al, 1992; Editorial, Lancet 1995).
Clearly, quality of life is the primary end point for many interven-
tions such aspalliative treatment. It is also critical where survival is
thought likely to be equivalent between arms ofa trial, forexample
when a more conservative treatment is being evaluated. Quality of
life is also a salient issue in a trial in which survival gains ofa new
treatment may be quite small and potentially offset by deterioration
in currentquality oflife. Forthe same reasons that treatment effects
upon survival are harder to determine in non-randomized designs
or in studies that are statistically underpowered, so too, where
quality of life is a clinical end point, it is unlikely to be appropriate
to 'bolt on' small-scale descriptive studies to address outcomes of a
treatment adequately in terms ofquality of life.
There are broader reasons that may justify the inclusion of
quality of life measures in clinical trials. Clinicians increasingly
face requests for information from patients about the likely course
oftheir illness or the consequences oftreatment, answers to which
can only be given accurately if such evidence has been gathered
systematically (Reynolds et al, 1981). There is also some evidence
that quality of life data may be of prognostic value (Ganz et al,
1991; Coates et al, 1993). Randomized controlled trials incorpo-
rating quality of life outcome measures have provided invaluable
information for such purposes (Hopwood and Stephens, 1995;
MRC Lung Cancer Working Party, 1996). However, these broader
objectives for increased understanding of quality of life in cancer
can be pursued in the context of observational studies as well as
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randomized controlled trials. A final specific reason for collecting
quality of life information in the context of a trial is if an economic
appraisal of costs and benefits of treatment options is needed. In
this case, the objective is to determine the overall social value of an
intervention in relation to competing health care priorities, and it is
generally necessary to collect a particular form of quality of life
data that provide evidence of the utilities of health outcomes, as
discussed below (Drummond, 1989; Morris and Goddard, 1993).
WHEN TO INCLUDE HEALTH ECONOMICS
While it is important to include consideration of health economics
at the design stage of clinical trials, it may not be appropriate to
include health economic assessments in all clinical trials. Two
questions need to be considered at the design stage of the trial
(Morris and Goddard, 1993; Drummond et al, 1994; Drummond,
1995). First, does the trial address issues that are of importance
economically? This may be because there are likely to be substan-
tial differences in the purchase costs or price ofthe interventions to
be studied, differences in the total costs of the interventions or
differences in the relative value for money of the interventions. If
there are no grounds for concern about these issues, then an
economic evaluation is unlikely to add further information of use
to health care decision makers and should not be undertaken. If
such concerns do exist, then the case for economic evaluation is as
strong as the case for assessing clinical effectiveness.
Secondly, will the results of the economic and clinical trial
inform the decisions to be made by one or more of the following:
clinicians; patients; purchasers or providers or policy makers?
This means that:
* the clinical objectives for the trial must be relevant for these
decision makers;
* the trial addresses clinical questions that are important deter-
minants of the relative value for money ofthe interventions;
* the trial compares the new treatment with one it is likely to
replace.
The objectives and designs of clinical trials to assess drug
activity or which are placebo controlled or feasibility studies may
be very focused and constrained. This means that they may not be
suitable for the integration of economic evaluations where the
objective is to provide rigorous and relevant information about the
relative value for money or cost-effectiveness of alternative inter-
ventions in routine practice (Coyle et al, 1998). For example, an
economic evaluation to assess the relative costs and benefits was
conducted alongside a clinical trial of the use of lenograstim in
patients receiving chemotherapy for small-cell lung cancer. A
primary objective ofthe clinical trial was to assess whether the use
oflenograstim would allow dose intensification ofa chemotherapy
regimen (VICE), which was in widespread use. The trial included
a relatively short length offollow-up (six cycles ofchemotherapy)
and proximal rather than final end points, which were appropriate
for the clinical objectives. However, they meant that the results of
the economic analysis were inconclusive (Drummond et al, 1994).
HOW TO ASSESS QUALITY OF LIFE
The patient should, whenever it is possible, be the source of any
assessment of his or her quality of life. Proxy judges such as rela-
tives, carers or health professionals cannot be expected to make
assessments as accurately. One particular problem is that signifi-
cant others tend to underestimate the quality oflife ofpatients with
cancer (Sprangers and Aaronson, 1992). Agreement between
patient and otherjudges of their quality of life may be greater for
more visible and concrete dimensions such as physical function
and less for more subjective dimensions such as psychological
mood. However, some patients will always find it difficult to
complete quality of life questionnaires because of their health
status, cognitive or linguistic difficulties or for other reasons.
Further research is still needed to specify the circumstances in
which proxyjudges' evidence can be used to reduce overall levels
of non-response. For example, it has been suggested that, while
clinicians are less accurate in assessing patients' states of quality
of life, they may make more accurate judgements of changes
(Regan et al, 1991).
There is now a substantial array ofquestionnaires and interview
schedules to assess quality of life in the field of cancer and health
care more generally (Fallowfield, 1990; Bowling, 1995). Many of
these instruments have been developed from careful 'bottom-up'
research examining the preferences and concerns ofpatients rather
than imposing the categories of clinicians. There is, therefore, a
growing body of evidence to determine the salient dimensions of
quality of life for particular forms of cancer. As a result, having
determined thatquality oflife is a relevant end point for atrial, it is
important that investigators make considered selections of
instruments relevant to the disease, characteristics of patients
and treatment options.
Questionnaires to assess quality of life in trials need to have
satisfactory psychometric properties in terms ofinternal reliability,
reproducibility, validity and sensitivity to significant changes over
time (Fitzpatrick et al, 1992). A variety of methods exist to
examine validity, but it is important to remember that an instru-
ment's validity is specific to a range ofpurposes and not a general
property. Face and content validity are of paramount importance.
By face validity is meant that items in an instrument should
measure clearly what is claimed. Content validity refers to how
well items adequately cover the range of issues in a domain such
as psychological well-being or social function.
Most instruments assess quality of life as a multidimensional
construct addressing aspects ofphysical, social and psychological
function as well as the experience of symptoms such as pain,
nausea and fatigue. Questionnaires may be one of four kinds: (1)
generic, intended to be applicable to a wide range of health prob-
lems; (2) disease- or diagnosis-specific; (3) dimension-specific,
addressing a single aspect of quality of life, most commonly
psychological well-being; and (4) utility based, in which addi-
tional information is obtained regarding utilities or preferences,
usually in the context ofeconomic appraisals.
Several instruments have now been used in the context of
cancer trials. As a generic instrument, the SF-36 includes 36 items
assessing eight dimensions ofhealth status (Ware and Sherbourne,
1992). It has been used successfully in a randomized trial of
follow-up care for breast cancer (Grunfeld et al, 1996). An
example ofa disease-specific instrument is the EORTC QLQ-C30,
a 30-item questionnaire assessing five domains of well-being in
cancer patients (Aaronson et al, 1993). It has been shown to be
valid in a variety offorms ofcancer (Begman et al, 1992; Bjordal
and Kaasa, 1992). Modules with additional questionnaire items
may be added to provide more specific assessments of particular
cancer sites. An example of a dimension-specific instrument is the
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Hospital Anxiety and Depression Scale, a 14-item assessment of
anxiety and depression (Zigmond and Snaith, 1983). It has been
shown to be of value in assessing these dimensions of well-being
in cancer patients (Ibbotson et al, 1994) and has been used in
randomized trials of breast cancer (Fallowfield et al, 1986;
Grunfeld et al, 1996). Methods are also beginning to emerge that
allow survival and quality of life to be considered together in
analysis of the effects of cancer treatments (Gelber et al, 1991).
The use ofutility-based quality of life measures by economists
in the context ofclinical trials needs to bedistinguished from other
measures ofhealth-relatedquality oflife. Utility measurements are
elicited from respondents to produce a single value for states of
health on a scale thattypically runs from 'dead' to 'perfect health'.
Such data may be combined with survival data to form outcome
indicators such as 'quality-adjusted lifeyears' (Williams and Kind,
1992). To obtain evidence from seriously illpatients of the 'trade-
offs' that they may make between survival and quality of life
clearly requires detailed and sensitive procedures that are usually
more time-consuming than standard quality of life questionnaires
(Froberg and Kane, 1989). An alternative is to use a self-
completed questionnaire such as EuroQol EQ SD (Brooks, 1996).
The core oftheEuroQol questionnaire is a set offivequestions, so
that it has the samerelatively short and easy tocomplete format as
quality oflife measuresalready cited. The answers toquestions are
weighted according to the values expressedby survey evidence of
the general population (Kind et al, 1994). Whether interviews are
used directly to elicit patients' values or a simpler questionnaire
such as EuroQol EQ 5D is used to estimate values, the overall
objective of this kind of measure is distinct; the purpose is to
produce a single overall value for health states in relation to a
treatment that may contribute to economic evaluations in the form
of cost-utility analysis of the treatment. There is less published
evidence to date ofthe use ofutility measures in cancer trials.
It is beyond the scope of this paper to examine the analysis of
quality of life data, but two methodological issues have yet to be
solved. First, there is a contentious debate about the appropriate-
ness and value of aggregating dimensions of quality of life to a
single state or value (Cox et al, 1992). Secondly, methods of
analysis need to bedeveloped to take account ofloss tofollow-up
and missing data, both of which can be a common problem for
quality of life assessments in cancer trials (Fallowfield, 1996).
HOW TO ASSESS COSTS
The costing methodology should be appropriate to the objectives
and null hypotheses ofthe economic and clinical studies. From the
economic perspective, the null hypothesis to be tested is of no
differences in the relative cost-effectiveness of the intervention
and control therapies, rather than no differences in costs or
outcomes per se. This requires measures of cost and outcome that
can be combined in formal cost-effectiveness ratios. For the
outcome measure, an instrument that can summarize a range of
complex outcomes and their impact on patient health status and
quality of life, such as utility measures, is preferable (Morris and
Goddard, 1993; Drummond, 1995).
The costs of the interventions studies should be calculated from
activity data, which quantify the levels of resources used, and sets
of price or unit cost data. All activity data are potentially impor-
tant, particularly where there is likely to be large variability in the
intensity of resource use between diseases, patients or between
centres. In particular, if cost-effectiveness ratios are to be calcu-
lated, it is important to maintain the internal link between cost and
effectiveness data by collecting and analysing activity and effec-
tiveness data for the same sample of patients. This means that,
where feasible, activity data should be collected for each patient
enrolled in the trial, for the full length of planned follow-up and
should include information on resources used for the management
ofadverse events, side-effects and treatment failure (Drummond et
al, 1994; Mauskopfet al, 1996).
Furthermore, activity data for non-health care services, such
as social services and informal care, should also be collected
(Drummond, 1995). For example, an economic evaluation was
conducted as an integral part of a large multicentre clinical trial of
continuous, hyperfractionated, accelerated radiotherapy (CHART)
(Morris and Goddard, 1993). It was decided to collect resource use
data for all patients in the trial for three reasons. First, the recruit-
ment of patients at each centre was low; secondly, the centres
varied in terms of location and organization; and, thirdly, the size
ofthe radiotherapy departments varied between the centres. These
factors meant that resource use data for a targeted subsample of
patients may not have been representative ofthe ten centres in the
trial. In addition, pilot studies indicated that it was important to
collect a wide range of resource use or activity data, including
hospital services, radiotherapy services, community health and
social services and patient travel.
However, ifthe collection ofthese additional data is not feasible
or may prejudice the clinical trial, serious consideration should be
given to alternative methods or studies for the collection of the
economic data. In particular, if reducing the range ofactivity data
collected means that it is not possible to answer the economic
questions posed with any confidence, it may be prudent to obtain
the economic data from other sources.
Data on the prices ofresources can be collected from secondary
data sources to help minimize the data collection burden on the
trial. However, the use of secondary data sources is only appro-
priate ifthe quality ofthe data is high and the data are a true reflec-
tion of the prices in the trial centres or are representative of
national prices (Morris and Goddard, 1993). Furthermore, the
prices used should allow the calculation of marginal resource
costs, as well as average costs (Dawson, 1994; Johanesson, 1994).
Marginal cost relates to the cost of resources used to produce one
extra unit of care or outcome. For example, the marginal cost of a
hospitalinpatientday atthe end ofan episode ofcare may be lower
than that of a day at the start of an episode of care, as different
amounts of care and resources may be required. Unless it can be
demonstrated that average and marginal prices are likely to be
equal, it may not be valid to mix average price data with marginal
resource use data. Currently, the data from secondary sources does
not fulfil any of these conditions. In particular, secondary sources
of cost data often combine a range of price data produced using
different methods of data collection and different methodologies.
Furthermore, prices may vary between centres because of differ-
ences in the way 'standard packages of care' are delivered. Until
accurate and valid information on means, variances and the rela-
tive prices of 'standard packages ofcare' is known, and the impact
of alternative costing methodologies on cost-effectiveness esti-
mates has been empirically tested, where feasible, price data
should be collected for each trial centre.
More generally, the design of a clinical trial needs to generate
economic results that are (1) internally valid in the sense that they
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can be accurately attributed to interventions studied and (2) exter-
nally valid in the sense of being generalizable beyond the trial
context to routine practice. The internal validity of the economic
results may be low ifthe sample size required to detect differences
in the clinical end points is not sufficient to detect statistically
significant differences in the economic end points. Furthermore,
pressure to keep the planned length of patient follow-up to a
minimum may result in censored or incomplete resource use and
outcome data. This would occur ifthe planned schedule offollow-
up does not allow measurement of the resource use and conse-
quences of clinical events, such as disease progression, lack of
therapeutic response or adverse side-effects, which are important
components of the overall costs of the interventions being
assessed. Furthermore, a short duration offollow-up may result in
the use ofproximal end points, such as tumourcontrol or treatment
intensity, rather than final end points, such as quality of life or
survival. Unless it can be demonstrated that the proximal end
points are directly related to the final endpoints, such as quality of
life or survival, this means that any differences in costs cannot
then be related to differences in patient benefit to assess relative
value for money.
The external validity ofthe results will be affectedby the design
and location of the trial, the trial protocol and the patient popula-
tion. In particular, strict inclusion and exclusion criteria and rigid
specification of patient care and management will reduce the
external validity of the clinical and economic results in terms of
patient population, clinical effectiveness and health care resource
use. Furthermore, the use of tests and diagnostic evaluations not
routinely used in regular practice may affect the estimates ofclin-
ical effectiveness and health care resource use by detecting disease
earlier or more accurately (Drummond and Davies, 1992;
Mauskopf et al, 1996).
FEASIBILITY OF TRIALS THAT INCLUDE
QUALITY OF LIFE AND HEALTH ECONOMIC
ISSUES
The integration of quality of life and health economics studies
with clinical trials requires careful consideration ofthe objectives,
methods, sample size and data requirements ofeach type ofstudy.
Although there are many similarities between each type ofevalua-
tion, there are also distinct differences, which will affect the feasi-
bility and relevance of integration. The integration of each type of
evaluation therefore needs individual consideration.
Quality of life
The protocol for the collection of quality of life data has to be
based on considerations of, on the one hand, what is scientifically
desirable to provide clear answers to questions and, on the other
hand, what is practically feasible in terms of patient burden and
disruption to clinical care. Evidence to assist trialists in finding
this balance is still not very extensive. Direct questioning of
patients' views about the acceptability of completing quality of
life assessments in a general medical setting found that the vast
majority viewed the task positively and thought the information
important for the clinician to know (Nelson et al, 1990). There is
evidence that patients with cancer may also consider their quality
of life to be important information for health care providers to
know (Fallowfield et al, 1987). However, there is also clear
evidence of declining response rates to quality of life question-
naires in cancer when the health ofpatients deteriorates, although
more research is needed to distinguish patients' own refusals from
health professionals' understandable reluctance to request partici-
pation from very ill respondents (Hopwood et al, 1994). Research
is also beginning to consider the validity of shorter assessments of
quality of life that reduce the burden to patients and investigators
(Katz et al, 1992).
It is increasingly clear that the inclusion of quality of life
measures is not a low-cost option, mainly because of the need for
trained staff to administer, process and interpret results. However,
it will be increasingly hard tojustify determining the inclusion of
other variables largely on scientific grounds and only quality of
life end points largely in terms ofresearch costs.
A key factor in overall cost and burden of a quality oflife study
is the sample size required forthe study to have the power to detect
a particular difference. Again, more evidence is needed to deter-
mine the clinical significance ofchanges in the scores ofquality of
life instruments, so that it becomes easier to estimate the sample
size likely to be needed to observe any particular clinically impor-
tant effect (Lydick and Epstein, 1993). Patients' judgements of
what is significant will need to be included in such work. Power
calculations are made more difficult because many data in this field
are not normally distributed, and parametric techniques of sample
size requirements may not be appropriate (Julious et al, 1995).
Health economics
As with quality of life studies, a balance needs to be found
between collecting information that can provide accurate and
conclusive answers to the economic questions addressed, mini-
mizing the cost of data collection and ensuring that the quality of
the clinical, quality of life and economic studies are not preju-
diced. Health economic evaluations address important policy
questions, which need to be evaluated rigorously and scientifically
and should not be precluded simply on the grounds of research
costs or difficulty.
The incorporation of economic evaluation requires the specifi-
cation of an efficient study design and sample size to ensure
internal validity and integration of the data collection effort to
minimize the burden on the trialists and patients.
At the design stage, attention needs to be paid to the specifica-
tion of prior expectations of quantities of resource use and the
costs of those resources to determine the likely key variables in
terms of volume and/or cost. In addition, knowledge of the likely
variance and variability of the economic variables is necessary.
This information can be gathered from existing literature or the
use of pilot studies (Morris and Goddard, 1993; Mauskopf et al,
1996). The data can then be used to determine both the minimum
sample size and the minimum data set required to address the
economic questions. In addition, the use of a range of sampling
strategies and study designs should be explored to ensure that trial
resources are used effectively. These may include the use of
unequal sample sizes for the control and intervention groups,
sampling different subgroups of patients at prespecified points in
time or the inclusion of an additional group of patients for the
purposes ofthe economic study only.
However, there may be situations in which the sample size of
the trial should be determined by economic ratherthan clinical end
points. This will depend upon the importance and relevance ofthe
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economic questions to be addressed. Consideration ofthese factors
requires a substantial amount of research to build the knowledge
base about average and marginal costs, the variation and disper-
sion ofresource use and costs and to test the validity of alternative
costing methodologies, study designs and sampling strategies.
SOME GENERAL PRINCIPLES
Bodies responsible for funding cancer trials will increasingly
expect research protocols to address quality of life and health
economic issues. This does not mean that every trial should
measure economic costs and quality of life, not least because this
would have difficult resource consequences for the overall port-
folio of cancer trials. Rather, it will be expected that the subjects
are explicitly considered in the protocol. It may therefore be
argued that they are not relevant issues for a particular trial, for
example, because sufficient is already known about the economic
costs or quality oflife implications of a particular treatment. It will
become increasingly difficult simply to omit the subject from any
consideration.
Incorporation of economic and quality of life studies should be
considered early in the design stage of each clinical trial.
The decision to incorporate either type of study should be based
on the following factors:
* the importance of the economic and quality of life questions to
be addressed by the study to patients, clinicians and policy
makers;
* the relevance of the objectives and hypotheses of the clinical
trial to the decisions to be made by patients, clinicians and
policy makers;
* the feasibility of incorporating the studies to ensure that the
results are internally valid and can provide conclusive answers
to the questions addressed.
ISSUES FOR FURTHER RESEARCH AND
DISCUSSION
Theconsultation process from which this paperemerged highlighted
two specific and fundamental areas in which there was no consensus
among participating experts and conflicting views in the literature,
for the most part arising from a lack ofavailable evidence.
First, it is not clear exactly when clinical trials do and do not
need to incorporate quality of life and health economic data. Some
discussion of this question has been included in this paper, and it
does need to be addressed separately in relation to the different
purposes to which quality oflife and economic data are likely to be
put. To some extent, it may not be possible to be more precise in
producing universal guidance as to when it is not important to
discover an unproved treatment's impact on quality of life as well
as on survival or its implications for societal resources. However,
whether the need for these additions to trial designs can only be
addressed on a 'case by case' basis is an important issue, not least
in relation to the need to make optimal use offinite research funds.
Secondly, there is no agreement about the scale and extent of
data collection needed to address these additional questions in the
context of a large randomized cancer trial. This problem is gener-
ally expressed in terms of excessive data regarding quality of life
and economic costs potentially jeopardizing the viability of a
clinical trial, either from burden to participants, additional research
costs or both. This way ofdefining the problem assigns primacy to
core clinical questions in such a way that additional data are
secondary as well as a potential 'burden' to trials. An alternative
and perhaps more appropriate way of formulating the problem
would be to consider the relative acceptability of the risks of
getting a wrong answer by having insufficient information, say,
about survival gains compared with resource consequences of a
new treatment. More accurate estimates are needed for those ques-
tions where the risks of not getting the right answer are less toler-
able. Whichever way this problem is formulated, there is no
consensus on how to determine appropriate volumes of data and
sample sizes. Efforts have been made to devise, for example,
feasible sampling strategies for patients and variables collected per
patient with the intention of reducing sample sizes required for
quality oflife and economic assessments to a few hundred patients
(Spiegelhalter et al, 1996).
The first of the two unresolved issues that we have identified -
when not to collect quality of life or economic data in the context
of a trial - may well have to be addressed at present in relation to
the specific clinical and therapeutic details ofeach trial separately.
The second question of how to devise optimal 'packages' of
survival, clinical, quality oflife and economic data may lend itself
to scientific methods of progressing. The NHS R&D HTA
programme has commissioned several systematic reviews to
address many of the methodological issues in clinical trials
addressed in this paper. They will be reported shortly. There may
also be scope for modelling and for reanalysis of trials that have
attempted to address the full range of variables. Ultimately, more
evidence from practice is needed to inform these aspects of the
conduct ofcancer trials.
Note: A workshop on health economics and quality of life in
cancer trials was organized by the United Kingdom Coordinating
Committee on Cancer Research (UKCCCR) and held on 26
February 1996. The following took part (from UK unless indi-
cated): N Aaronson (Netherlands), M Buxton, H Campbell, P Coe,
D Cohen, D Cox, L Davies, I Evans, L Fallowfield, R Fitzpatrick,
S Gore, R Gray, I Hammond, P Hopwood, W Kiebert (Belgium),
D Machin, A McGuire, J Mossman, C Normand, L O'Toole, A
Ramirez, M Richards, R Stephens, N Thatcher, K Torfs (Belgium),
J Yamold, J Toy and P Twentyman. Although this paper has been
through three drafts in direct response to participants' comments,
it cannot be inferred that the whole content is endorsed by every
participant.
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